Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk

A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.

Investors Business Daily

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Fortune

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.

Investors Business Daily

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Approved weight-loss drug contributed to UK nurse’s death, report says

Susan McGowan took two doses of tirzepatide, under Mounjaro brand, before she died in North Lanarkshire

The Guardian - UK

Scottish nurse’s death linked to approved weight-loss drug

THE death of a Scottish nurse has been linked to a weight-loss drug approved on the NHS.

The National (Scotland)

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Midday stock movers: Alphabet, Super Micro, Eli Lilly and more

Here are the stocks making the biggest market moves.

The Street

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs.

Investors Business Daily

ResMed Breaks Out As GLP-1 Drugs And Big Tech Help Drive A Quarterly Beat

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Fact check: Weight loss drug trial, US election rules and ‘IDF soldiers’ image

Round up of fact checks from the last week compiled by Full Fact.

Investors Business Daily

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

StockNews.com

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

The National (Scotland)

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

THE UK’s Health Secretary has denied his plans to give weight-loss jabs to unemployed people would result in a “dystopian future”.

The Guardian - UK

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The National (Scotland)

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

LABOUR plans to give obese and unemployed people weight-loss jabs as part of a drive to get them back into work and reduce pressure on the NHS…

Investors Business Daily

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

The National (Scotland)

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

Investors Business Daily

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

1 2 3 4 5

People

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations